AC Immune S.A. (ACIU) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	17.5M	3.6M	27.3M	14.8M	3.9M
Cost of Revenue	—	—	62.6M	54.6M	—
Gross Profit	17.5M	3.6M	(35.3M)	(39.8M)	3.9M
Operating Expenses
R&D Expense	45.8M	56.4M	62.6M	54.6M	60.3M
SG&A Expense	11.0M	11.7M	11.4M	10.6M	9.6M
General & Admin Expense	11.0M	11.7M	11.4M	10.6M	9.6M
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	4.8M	4.3M	(56.9M)	(51.4M)	4.9M
Total Operating Expenses	61.7M	72.4M	17.1M	13.8M	74.8M
Cost and Expenses	61.7M	72.4M	79.7M	68.4M	74.8M
Operating Income (EBIT)	(44.2M)	(68.9M)	(52.4M)	(53.6M)	(70.8M)
Non-Operating
Interest Income	1.1M	1.9M	3.2M	1.0M	69.0K
Interest Expense	167.7K	191.0K	133.0K	176.0K	355.0K
Net Interest Income	901.6K	1.7M	3.1M	868.0K	(286.0K)
Other Non-Op Income/Expense	1.0M	(1.6M)	1.5M	(599.0K)	107.0K
Non-Operating Income (excl Interest)	(1.2M)	1.4M	(1.6M)	423.0K	(462.0K)
EBT (Pre-Tax Income)	(43.2M)	(70.4M)	(50.9M)	(54.2M)	(70.7M)
Income Tax Expense	—	—	3.0K	10.0K	13.0K
Bottom Line
Net Income	(43.2M)	(70.4M)	(50.9M)	(54.2M)	(70.8M)
Earnings from Cont. Ops	(43.2M)	(70.4M)	(50.9M)	(54.2M)	(70.8M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(43.2M)	(70.4M)	(50.9M)	(54.2M)	(70.8M)
Per Share
Basic EPS	($0.43)	($0.70)	($0.51)	($0.64)	($0.85)
Diluted EPS	($0.43)	($0.70)	($0.51)	($0.64)	($0.85)
Revenue Per Share	$0.18	$0.04	$0.27	$0.17	$0.05
Shares
Basic Shares Outstanding	98.7M	100.8M	99.7M	84.7M	83.6M
Diluted Shares Outstanding	98.7M	100.8M	99.7M	84.7M	83.6M
Profitability Metrics
EBITDA	(42.0M)	(67.8M)	(48.6M)	(51.8M)	(68.0M)
D&A	990.0K	2.5M	2.2M	2.2M	2.4M
EBIT	(43.0M)	(70.3M)	(50.8M)	(54.0M)	(70.4M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026